Outcomes of infants born in 2019 to persons infected with hepatitis B virus and managed by CDC Perinatal Hepatitis B Prevention Program through the end of 2020, 64 US Jurisdictions

Print
Related Pages
◀ Figure 4.1
Appendix ▶

Outcomes of infants born in 2019 to persons infected with hepatitis B virus and managed by CDC Perinatal Hepatitis B Prevention Program through the end of 2020, 64 US Jurisdictions

Hepatitis B vaccine administration Post-vaccination serologic testing
Grantee All infants managed HBIG & vaccine at birth Complete series by 12 months of age Complete series after 12 months of age Total with complete series Received† HBsAg positive Immune§
No. No. % No. % No. % No. % No. % No. % No. %
Outcomes of infants born in 2018 to hepatitis B infected persons and managed by the CDC Perinatal Hepatitis B Prevention Program through the end of 2019, 64 U.S. Jurisdictions
All Jurisdictions 9,055 8,709 96% 7,653 85% 131 1% 7,784 86% 5,759 64% 16 0% 5,523 96%
State
Alabama 78 78 100% 30 38% 0 0% 30 38% 24 31% 0 0% 11 46%
Alaska 28 27 96% 25 89% 1 4% 26 93% 17 61% 0 0% 17 100%
Arizona 133 119 89% 103 77% 10 8% 113 85% 64 48% 0 0% 59 92%
Arkansas 61 60 98% 45 74% 0 0% 45 74% 40 66% 1 3% 37 93%
California 1,600 1,551 97% 1,204 75% 6 0% 1,210 76% 908 57% 2 0% 866 95%
Colorado 111 111 100% 108 97% 1 1% 109 98% 100 90% 0 0% 99 99%
Connecticut 40 38 95% 1 3% 1 3% 2 5% 1 3% 0 0% 1 100%
Delaware 45 45 100% 26 58% 12 27% 38 84% 38 84% 0 0% 34 89%
Florida 394 347 88% 298 76% 2 1% 300 76% 96 24% 0 0% 90 94%
Georgia 283 270 95% 258 91% 2 1% 260 92% 230 81% 1 0% 222 97%
Hawaii 139 137 99% 131 94% 2 1% 133 96% 114 82% 0 0% 113 99%
Idaho 17 16 94% 16 94% 0 0% 16 94% 11 65% 0 0% 11 100%
Illinois 162 160 99% 144 89% 1 1% 145 90% 99 61% 0 0% 92 93%
Indiana 117 117 100% 113 97% 0 0% 113 97% 86 74% 1 1% 85 99%
Iowa 121 119 98% 111 92% 0 0% 111 92% 73 60% 0 0% 68 93%
Kansas 44 43 98% 39 89% 1 2% 40 91% 27 61% 0 0% 19 70%
Kentucky 60 55 92% 48 80% 2 3% 50 83% 30 50% 0 0% 29 97%
Louisiana 123 108 88% 103 84% 5 4% 108 88% 63 51% 2 3% 57 90%
Maine 10 10 100% 10 100% 0 0% 10 100% 7 70% 0 0% 7 100%
Maryland 253 239 94% 210 83% 7 3% 217 86% 158 62% 0 0% 151 96%
Massachusetts 307 303 99% 291 95% 0 0% 291 95% 271 88% 0 0% 265 98%
Michigan 152 152 100% 140 92% 2 1% 142 93% 121 80% 0 0% 118 98%
Minnesota 398 395 99% 376 94% 5 1% 381 96% 304 76% 0 0% 298 98%
Mississippi 54 51 94% 41 76% 1 2% 42 78% 31 57% 0 0% 29 94%
Missouri 84 81 96% 72 86% 1 1% 73 87% 48 57% 0 0% 43 90%
Montana 10 9 90% 6 60% 0 0% 6 60% 4 40% 0 0% 4 100%
Nebraska 62 43 69% 56 90% 0 0% 56 90% 44 71% 0 0% 42 95%
Nevada 82 82 100% 81 99% 0 0% 81 99% 59 72% 0 0% 58 98%
New Hampshire 16 16 100% 10 63% 0 0% 10 63% 7 44% 0 0% 7 100%
New Jersey 271 244 90% 196 72% 10 4% 206 76% 98 36% 0 0% 88 90%
New Mexico 11 9 82% 10 91% 1 9% 11 100% 9 82% 0 0% 7 78%
New York State 218 205 94% 201 92% 1 0% 202 93% 166 76% 0 0% 163 98%
North Carolina 191 184 96% 174 91% 4 2% 178 93% 122 64% 0 0% 119 98%
North Dakota 36 35 97% 27 75% 5 14% 32 89% 15 42% 0 0% 15 100%
Ohio 269 264 98% 223 83% 2 1% 225 84% 113 42% 2 2% 102 90%
Oklahoma 69 67 97% 61 88% 2 3% 63 91% 46 67% 0 0% 45 98%
Oregon 50 40 80% 39 78% 4 8% 43 86% 0 0% 0 0% 0 0%
Pennsylvania 191 189 99% 171 90% 4 2% 175 92% 113 59% 0 0% 112 99%
Rhode Island 35 35 100% 33 94% 0 0% 33 94% 27 77% 0 0% 25 93%
South Carolina 64 59 92% 51 80% 1 2% 52 81% 36 56% 0 0% 36 100%
South Dakota 16 16 100% 16 100% 0 0% 16 100% 10 63% 0 0% 10 100%
Tennessee 117 113 97% 113 97% 2 2% 115 98% 78 67% 0 0% 74 95%
Texas 539 519 96% 462 86% 2 0% 464 86% 377 70% 0 0% 363 96%
Utah 77 76 99% 71 92% 1 1% 72 94% 43 56% 0 0% 43 100%
Vermont 5 5 100% 5 100% 0 0% 5 100% 1 20% 0 0% 0 0%
Virginia 243 229 94% 228 94% 2 1% 230 95% 146 60% 0 0% 141 97%
Washington U U U U U U U U U U U U U U U
West Virginia 21 21 100% 21 100% 0 0% 21 100% 19 90% 0 0% 19 100%
Wisconsin 142 142 100% 131 92% 3 2% 134 94% 95 67% 2 2% 92 97%
Wyoming 3 3 100% 2 67% 1 33% 3 100% 1 33% 0 0% 1 100%
City**
Chicago 102 101 99% 78 76% 0 0% 78 76% 70 69% 0 0% 69 99%
District of Columbia 27 27 100% 25 93% 0 0% 25 93% 22 81% 0 0% 22 100%
Houston 119 113 95% 98 82% 4 3% 102 86% 87 73% 0 0% 85 98%
New York City 1,031 1,028 100% 949 92% 5 0% 954 93% 875 85% 0 0% 856 98%
Philadelphia 128 111 87% 103 80% 7 5% 110 86% 84 66% 0 0% 78 93%
San Antonio 36 36 100% 30 83% 2 6% 32 89% 25 69% 0 0% 25 100%
Territory
American Samoa 3 3 100% 3 100% 0 0% 3 100% 0 0% 0 0% 0 0%
Guam 12 12 100% 3 25% 4 33% 7 58% 0 0% 0 0% 0 0%
N. Mariana Islands 5 5 100% 5 100% 0 0% 5 100% 5 100% 5 100% 0 0%
Puerto Rico 1 1 100% 1 100% 0 0% 1 100% 0 0% 0 0% 0 0%
Virgin Islands 1 1 100% 1 100% 0 0% 1 100% 1 100% 0 0% 1 100%
Freely Associated Island Nations
Republic of the Marshall Island U U U U U U U U U U U U U U U
Micronesia 35 32 91% 23 66% 2 6% 25 71% 0 0% 0 0% 0 0%
Palau 3 2 67% 3 100% 0 0% 3 100% 0 0% 0 0% 0 0%
Download Data (xlsx)

Downloads of this table: PDF  PPT

HBIG=hepatitis B immune globulin

HepB=hepatitis B vaccine

HBsAg=hepatitis B surface antigen

anti-HBs= antibody to hepatitis B surface antigen

U= The data were unavailable

* These data only include infants followed by the PHBPP. National and jurisdictional level HepB vaccination coverage rates are available via annual MMWR publications of National Immunization Survey data and via VaxView.

† Post vaccination serologic testing includes a test for HBsAg, anti-HBs, or both. Results from post vaccination serologic testing may be reported as HBsAg positive, HBsAg negative and immune or not immune, or indeterminate.

§ Anti-HBs >10 mIU/mL

¶ Percentage is among infants that completed the vaccine series and received PVST.

** City data are mutually exclusive from state data.

This table summarizes outcome data on infants born to persons with hepatitis B virus infection from the CDC Perinatal Hepatitis B Prevention Program. The 2019 birth cohort includes infants born in 2019 and followed through December 31, 2020.

Among the 9,055 infants whose care was managed by the Perinatal Hepatitis B Prevention Program, 96% received recommended prophylaxis at birth, 85% completed the vaccine series (regardless of prophylaxis), and 64% received recommended post-vaccination serologic testing.

Among infants who received post-vaccination testing (5,759), there were 16 (0.3%) cases of perinatal hepatitis B transmission; the proportion of infants testing positive for hepatitis B was lower among those who received prophylaxis within 1 day of birth (14/5,815, 0.2%) compared to those who did not (2/105, 1.9%).

Figures